CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS) today announced the presentation of new data on SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback